Evidence map›Paper›PMID 31598208›Full record

ArticleRare tumors2019

Giant cell tumor of bone: Unusual features of a rare tumor.

Ziyad M Mohaidat, Hisham Z Al-Jamal, Audai M Bany-Khalaf, Ahmad M Radaideh, Ziad A Audat

Abstract read
In one paragraph

Article in Rare tumors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Rare features of giant cell tumors of the bone: A case report.Experimental and therapeutic medicine · 2024
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. MiR-217 regulates autophagy through OPG/RANKL/RANK in giant cell tumors.Journal of orthopaedic surgery and research · 2023
    Article
  12. Diagnostic value ofJournal of bone oncology · 2023
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Giant cell tumor of the sacrum.Proceedings (Baylor University. Medical Center) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ziyad M MohaidatOrthopedic Surgery Division, Department of Special Surgery, Jordan University of Science & Technology, Irbid, Jordan.ORCID https://orcid.org/0000-0003-0474-2645
Hisham Z Al-JamalOrthopedic Surgery Division, Department of Special Surgery, Jordan University of Science & Technology, Irbid, Jordan.ORCID https://orcid.org/0000-0001-5151-4595
Audai M Bany-KhalafOrthopedic Surgery Division, Department of Special Surgery, Jordan University of Science & Technology, Irbid, Jordan.ORCID https://orcid.org/0000-0003-4565-6890
Ahmad M RadaidehOrthopedic Surgery Division, Department of Special Surgery, Jordan University of Science & Technology, Irbid, Jordan.
Ziad A AudatOrthopedic Surgery Division, Department of Special Surgery, Jordan University of Science & Technology, Irbid, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Giant cell tumor of bone is a benign tumor with an aggressive behavior. Its typical subarticular location and high recurrence risk can be associated with significant morbidity. Although benign, it can rarely metastasize especially to the lungs. Also, it can be multicentric in less than 1% of patients. Late malignant transformation, although rare, can occur with a very poor prognosis. This series reports on these unusual and challenging features and management considerations of giant cell tumor of bone. This retrospective study included review of the medical records of patients with a confirmed histopathological diagnosis of giant cell tumor of bone. A total of 25 patients (16 females and 9 males) with a mean age of 34.5 years were included; 22 had primary tumors, while 3 were referred with recurrent tumors. Pain was the most common presenting symptom. Most patients had grade III tumors. Tumors around the knee were the most common. Multicentric tumors were detected in three patients. Twenty-three patients (20 primary giant cell tumor of bone and 3 with recurrence) received treatment. Most patients (15/23) were treated with intralesional curettage with or without adjuvants. Seven patients had wide excision. Recurrence was seen in 45% (9/20) of primary giant cell tumor of bone especially with difficult anatomical locations. Most recurrences occurred more than 4 years after treatment. Pulmonary nodules were detected in four patients; two of them showed resolution during follow-up. One patient developed secondary sarcoma transformation with a fatal outcome. Giant cell tumor of bone was more common in females. Long bones were more affected, especially around the knee. Intralesional curettage was the most frequently used treatment. Recurrence was associated with inadequate tumor resection (especially in difficult anatomical location), younger age, male gender, and advanced local tumor grade. Denosumab can be used in the treatment of pulmonary metastasis, multicentric and recurrent giant cell tumor of bone. Due to late recurrence and malignant transformation, a prolonged follow-up is warranted.

Indexed as

denosumabGiant cell tumor of bonemalignant giant cell tumor of bonemulticentric giant cell tumor of bonepulmonary metastasis

Identifiers

PMID31598208
PMCPMC6764048

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.